Ruiz-Moreno José M, Montero Javier A, Zarbin Marco A
Department of Ophthalmology, Miguel Hernández University School of Medicine, Alicante, Spain.
Retina. 2007 Apr-May;27(4):458-61. doi: 10.1097/IAE.0b013e318030c77c.
To evaluate the efficacy of photodynamic therapy (PDT) and high-dose intravitreal triamcinolone acetonide (TA) injection to treat choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) at the 2-year follow-up.
In this prospective, consecutive, comparative, nonrandomized, interventional case series, 30 eyes of 30 consecutive patients with subfoveal CNV associated with AMD were treated by PDT followed by intravitreal injection of 19.4 +/- 2.1 mg TA. Fifteen eyes were naive to treatment (group 1), and 15 had been treated previously by PDT alone (group 2). A group of 15 eyes of 15 patients treated by PDT alone served as controls. The number of Snellen lines gained or lost and PDT sessions were evaluated.
Best-corrected visual acuity (BCVA) did not change significantly in group 1 from baseline (0.0 +/- 3.4 Snellen line; range, -5 to 9 Snellen lines; P = 0.81); group 2 lost an average -0.6 +/- 2.5 line (range, -7 to 3 Snellen lines) (P = 0.41), and the control group lost an average of -2.2 +/- 3.4 lines (range, -8 to 2 Snellen lines) (P = 0.03, Wilcoxon signed rank test). The average number of PDT sessions during the 24-month follow-up was 1.9, 1.2, and 3.9 for group 1, group 2, and the control group, respectively.
Two years after combined PDT/high-dose intravitreal TA to treat AMD-associated CNV, final BCVA was stable, and the need for retreatment was reduced compared with historical controls.
在2年随访期评估光动力疗法（PDT）和玻璃体内注射高剂量曲安奈德（TA）治疗年龄相关性黄斑变性（AMD）相关脉络膜新生血管（CNV）的疗效。
在这个前瞻性、连续性、对比性、非随机、干预性病例系列中，30例连续的伴有AMD的黄斑中心凹下CNV患者的30只眼接受了PDT治疗，随后玻璃体内注射19.4±2.1mg TA。15只眼为初次治疗（第1组），15只眼曾单独接受过PDT治疗（第2组）。15例患者单独接受PDT治疗的15只眼作为对照组。评估Snellen视力行数的增减情况以及PDT治疗次数。
第1组最佳矫正视力（BCVA）与基线相比无显著变化（0.0±3.4 Snellen行；范围为-5至9 Snellen行；P = 0.81）；第2组平均下降0.6±2.5行（范围为-7至3 Snellen行）（P = 0.41），对照组平均下降2.2±3.4行（范围为-8至2 Snellen行）（P = 0.03，Wilcoxon符号秩检验）。在24个月随访期间，第1组、第2组和对照组的PDT平均治疗次数分别为1.9次、1.2次和3.9次。
联合PDT/玻璃体内高剂量TA治疗AMD相关CNV两年后，最终BCVA稳定，与历史对照相比，再次治疗的需求减少。
